Drugs for a new millennium
Open Access
- 29 December 1999
- journal article
- review article
- Published by The Royal Society in Philosophical Transactions Of The Royal Society B-Biological Sciences
- Vol. 354 (1392) , 1985-1994
- https://doi.org/10.1098/rstb.1999.0538
Abstract
A millennium, a century, even a decade is a long time–frame for speculation about anything. Advances in biomedical research in the last few decades have been so extraordinary and escalating at an ever–accelerating pace that any prophecy is a risky proposition. However, it is possible to divine the big, unanswered questions and envisage ways in which they might reasonably be approached in the next few decades, a task which I will try to essay. So many drugs treat so many different medical conditions that a detailed and comprehensive coverage would probably be tiresome. Instead, I will address certain broad themes and diseases that offer both immense challenges and great potential for advances. Rather than review detailed experimental issues, I will confine myself to the ‘big picture’ issues, providing examples of specific research only in a few instances drawing largely from areas I know best.Keywords
This publication has 6 references indexed in Scilit:
- The PsychopharmacologistsPublished by Taylor & Francis ,2018
- Poly (ADP-ribose) polymerase, nitric oxide and cell deathTrends in Pharmacological Sciences, 1999
- Dissection of Dopamine and Cocaine Binding Sites on the Rat Dopamine Transporter Expressed in COS CellsaAnnals of the New York Academy of Sciences, 1996
- Excitatory Amino Acids as a Final Common Pathway for Neurologic DisordersNew England Journal of Medicine, 1994
- Interactions between glutamatergic and monoaminergic systems within the basal ganglia-implications for schizophrenia and Parkinson's diseaseTrends in Neurosciences, 1990
- The current status of the dopamine hypothesis of schizophreniaNeuropsychopharmacology, 1988